NIDA Neuroscience Grants and RFAs

1 post / 0 new
R Bishop
R Bishop's picture
NIDA Neuroscience Grants and RFAs

Please find below many new NIDA RFAs and access to the NIH Guide for more information for all NIH FOAs
RFA-DA-08-024- Extinction and Pharmacotherapies for Drug Addiction (Now accepting applications through
Opening Date: January 27, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent January 28, 2008
(Last) Application Submission/Receipt Date(s): February 27, 2008
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate animal or human research on mechanisms underlying extinction in order to guide the development of interventions for enhancing extinction of drug-seeking behavior. It is expected that research supported under this FOA will ultimately be used to guide and implement combined behavioral/cognitive and pharmacological/molecular interventions for the treatment of drug abuse relapse.
Mechanism of Support: This FOA will utilize the NIH Research Project Grant (R01) see: RFA-DA-08-024, or R03 grant mechanism: RFA-DA-08-025
Budget and Project Period: For the R03, budgets for direct costs of up to $125,000 per year and project duration of up to two years may be requested. For the R01, standard NIH Guidelines apply.
Funds Available and Anticipated Number of Awards. It is anticipated that $1.5 million in total costs will be awarded to 4-6 applications for this FOA
-----
RFA-DA-08-014 Substance Abuse and Glial Regulation of Nervous System Function
Opening Date: February 13, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): February 13, 2008
Application Submission/Receipt Date: March 13, 2008.
The goal of this FOA is to encourage basic research project applications that will enhance and increase current understanding of the structural and functional interactions between glial and neuronal cells, and the effects and consequences of substance abuse on these interactions within the central and peripheral nervous systems
Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with two additional FOAs of identical scientific scope, RFA-DA-08-015 and RFA-DA-08-013, which solicit applications under the NIH Research Project Grant (R21) and (R03) award mechanisms, respectively.
Funds Available and Anticipated Number of Awards. NIDA intends to commit approximately $3,000,000 in FY2008 to support a total of 10-12 new grants in response to this FOA and the two parallel FOAs. The INMHA will consider co-funding meritorious applications in this area involving Canadian scientists and institutions. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications
------

PAS-07-327 Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R03)
Purpose. The National Institute on Drug Abuse (NIDA), through the issuance of this program announcement, with set aside funds (PAS), seeks to facilitate the entry of beginning investigators into basic chemistry research applied to drug abuse and addiction. NIDA invites newly independent investigators to submit applications for exploratory, or pilot research projects related to NIDAs mission.
Mechanism of Support. This FOA will utilize the NIH Small Research Grant (R03) award mechanism.
The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.
The R03 is not renewable.
Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 4-6 projects awarded as a result of this announcement is $1,500,000 for fiscal year 2007.
Budget and Project Period. Budgets for direct costs of up to $125,000 per year and a project duration of up to two years may be requested for a maximum of $250,000 direct costs over a two-year project period.
----
PAR-08-081 Research Education Grants for Statistical Training in the Genetics of Addiction (R25)

Release/Posted Date: January 28, 2008
Opening Date: February 18, 2008 (Earliest date an application may be submitted to Grants.gov)
Application Submission/Receipt Date(s): March 18, 2008, March 17, 2009, March 17, 2010
Purpose. This FOA invites applications focused on research education for the development and testing of new statistical models to address genetics-based research problems in addiction. Applicants are expected to propose a well-integrated research education and training program in statistical models or computational methods in genetics for undergraduate, graduate, and/or postdoctoral level students. Since this is a novel program, participants may be supported for as long as five years, however shorter durations of funding of some individual participants are encouraged. Achieving the capacity of the institution to address the identified research area(s) is an additional goal of this award. During this award, institutions will be expected to implement strategies for enhancing research infrastructure and capacity building at their institution and in collaborative activities.
Mechanism of Support. This FOA will use the NIH Research Education (R25) grant mechanism.
Budget and Project Period: The total project period for an application submitted in response to this funding opportunity may not exceed five years. The estimated amount of funds available for the support of projects awarded as a result of this announcement is approximately $600,000 for fiscal year 2008. For this FOA, future amounts will depend on annual appropriations, but are expected to be the same. All personnel costs (including administrative and clerical costs, as well as salaries of the PD/PI and other investigators/faculty) associated with directing, coordinating, and administering the Program should be justified and reasonable. Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; State Government; and Eligible agencies of the Federal government. Foreign institutions are not eligible.
Eligible Project Directors/Principal Investigators (PDs/PIs). Any individual with the skills, knowledge, and resources necessary to carry out the proposed research education program is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Eligible program directors/mentors must be established researchers with acknowledged accomplishments in new statistical methods and computational models development and genetics research and training with the ability to assemble experts and develop curricula appropriate to this initiative.
Eligible Participants. Eligible participants include individuals at all stages of the career continuum (undergraduate, graduate, and/or postdoctoral level students) and may include both US and non-US citizens.
Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.
----
RFA-DA-08-010 The National Institute on Drug Abuse HIV/AIDS Pilot Proteomics Centers (P20)

Release Date: December 17, 2007
Letters of Intent Receipt Date: February 27, 2008
Application Receipt Date: March 27, 2008
This Funding Opportunity Announcement (FOA) issued by NIDA, National Institutes of Health, solicits applications to establish Pilot Proteomics Centers that will address the complex biological mechanisms of interactions among drugs of abuse and HIV pathogenesis, their treatments, and host responses. The centers will use proteomics technologies and other related technologies (i.e., gene expression profiling) to look for protein changes and molecular signatures of disease progression of HIV/AIDS in combination with substance abuse/addiction, HIV treatment, and/or treatments for substance abuse. These proteomics centers are expected to help identify mechanisms related to susceptibility to and progression of HIV infection, viral replication, and viral evolution, particularly related to neuroAIDS. The use of advanced tools to better understand the molecular and cellular consequences of HIV-1 infection and substance abuse in the era of HAART will likely lead to the identification of new biomarkers for disease progression and new avenues for clinical research and interventions.
The total amount to be awarded is $2,000,000 to support one or two centers using the P20 mechanism. Individual awards will be limited to $700,000 direct costs for each of three years.
Eligible organizations include: Public/State Controlled Institution of Higher Education, Private Institution of Higher Education, Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education), Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education), Small Business, For-Profit Organization (Other than Small Business), State Government, U.S. Territory or Possession, Indian/Native American Tribal Government (Federally Recognized), Indian/Native American Tribal Government (Other than Federally Recognized), Indian/Native American Tribally Designated Organization.
Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research.
Renewals and Resubmissions. Neither renewals or resubmissions will be accepted for this FOA.
Applicants may submit more than one application, provided they are scientifically distinct.
-------------
RFA-DA-08-009 HIV-1 and Host Genetics in Drug Using Populations and Model Organisms (R01)
Release Date: December 27, 2007
Opening Date: Month, day, year (Earliest date an application may be submitted to Grants.gov) February 27, 2008
Letters of Intent Receipt Date(s): February 27, 2008
Application Submission/Receipt Date(s): March 27, 2008
Purpose. This Funding Opportunity Announcement (FOA) issued by NIDA, National Institutes of Health, solicits Research Project Grant applications that propose to elucidate the molecular mechanisms by which genetic variations provide protection from or vulnerability to infection, and how drugs of abuse, medications for drug addiction, and HIV-1 treatment interact with both host and viral genes.
Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism.
Funds Available and Anticipated Number of Awards. A total of $2M is available under this FOA contingent upon the submission of a sufficient number of meritorious applications. The anticipated number of awards under this FOA is 4-7.
Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.
Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.
Renewals and Resubmissions. Neither competing renewal (formerly competing continuation) nor resubmission (formerly revised) applications will be accepted for this FOA. At this time it is not known whether this FOA will be reissued.
-----------
RFA-DA-08-020 Facilitating Self-Control of Substance Abuse Related Brain Activity Through Real-Time Monitoring of fMRI Signals (R21/R33)
Opening Date: February 14, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): February 14, 2008
NOTE: On time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Submission/Receipt Date(s): March 14, 2008
Peer Review Date(s): June 2008
Council Review Date(s): August 2008
Earliest Anticipated Start Date(s): September 2008
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: March 15, 2008
Purpose. The National Institute on Drug Abuse (NIDA), through the issuance of this Request for Applications (RFA), seeks to encourage exploratory (i.e., descriptive, hypothesis-generating, and developmental) research focusing on the use of real time functional magnetic resonance imaging (rt-fMRI) in humans so that subjects can learn to modulate their own brain activity and monitor and control (modulate) activity of brain regions relevant to substance abuse. Proposals may incorporate development, implementation, and dissemination of requisite technology and methods as well as feasibility testing in healthy human subjects or substance abusers. Because applications are to be exploratory in nature, pilot data that provide support for the proposed hypotheses and aims (i.e., Proof of Concept) are not required nor is it expected that data to support the hypotheses be provided. However, applicants are encouraged to provide evidence that they have the capability to conduct fMRI studies (i.e., Proof of Feasibility) by documenting the availability of needed resources, the training and experience of the investigative team, and/or the conduct of related studies. Such studies would be optimally conducted by interdisciplinary teams that include researchers with brain imaging, cognitive neuroscience, behavioral analysis, and treatment expertise, Investigators from different institutions may submit linked applications to support collaborative projects.
Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH R21/R33 Phased Innovation Award ((R21 [Phase I]/R33 [Phase II]) grant mechanism. The Phased Innovation (R21/R33) mechanism provides support for a first phase (R21) for technical development and a second phase (R33) for technology application and demonstration of utility in a larger subject sample. The outcome of the first phase (R21) should be data demonstrating the feasibility of the technology or approach proposed for the second phase, and the second phase (R33) should have the goal of generating proof-of-concept data.
Funds Available and Anticipated Number of Awards. This FOA has $3M set aside to fund meritorious applications that address the goals of this solicitation.
----------

For information on other NIDA and NIH active FOAs please visit http://grants.nih.gov/grants/guide/
-------------

Jonathan D. Pollock, Ph.D.
Chief
Genetics and Molecular Neurobiology Research Branch
Division of Basic Neuroscience and Behavioral Research
6001 Executive Blvd
Bethesda, MD 20892
tel. 301-435-1309
fax. 301-594-6043
email. eval(unescape('%64%6f%63%75%6d%65%6e%74%2e%77%72%69%74%65%28%27%3c%61%20%68%72%65%66%3d%22%6d%61%69%6c%74%6f%3a%6a%70%6f%6c%6c%6f%63%6b%40%6d%61%69%6c%2e%6e%69%68%2e%67%6f%76%22%3e%6a%70%6f%6c%6c%6f%63%6b%40%6d%61%69%6c%2e%6e%69%68%2e%67%6f%76%3c%2f%61%3e%27%29%3b'))